ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / PEPG / insiders
CNTN (33) ANTX (43) ORMP (33) YARW (26) ⌘ Pro Terminal β†’

PepGen Inc. (PEPG) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$2.35 -0.42% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.34

PepGen Inc. (PEPG) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- β€’ RED ALERT Cap $162.8M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PEPG Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is PEPG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, PepGen Inc. (NASDAQ: PEPG) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $2.35 (-0.42% 1D, market cap $162.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, PEPG ranks #598 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does PEPG compare to CNTN and ANTX in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PEPG carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, CNTN (Canton Strategic Holdings Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -4.1%, cap $162.5M) and ANTX (AN2 Therapeutics Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $164.2M). Among the 5-stock peer group, PEPG leads on earnings multiple (N/A) while CNTN leads on capital efficiency (-4.1% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PEPG?
β–Ό

Per PEPG's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001835597), PepGen Inc. generated $262.1M in revenue (-4.2% YoY), -$89.7M in net income, and -$81.9M in free cash flow against $173.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.34 (-0.27%)🧬 Disciplined Float (+0.72% YoY Shares)βš™οΈ Cash Engine: 7/20 (D-) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (35/100 Β· D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ D-
025507510035
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk D
Cash (7)Whales (3)SEC (10)Macro (10)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-10.2% Base Target
$8 Bull$2 Base$2 Bear
πŸ“¬ FREE PEPG RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for PEPG)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (35/100 Composite)
πŸ” WHY PEPG SCORES 35/100 (D-) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 3/9

β–² #2 Bullish Driver: Macro Regime Fit+10/20 pts (29% of score)

FRED Regime Γ— Technicals: 16% of 52W Range β€’ RSI-14 at 41.6 (NEUTRAL RANGE)

β–Ό #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
27
Grade E$2.32+17.2% Next Q
Q2 (-2Q)
30
Grade E$2.72-7% Next Q
Q3 (-1Q)
32
Grade E$2.53-7.1% Next Q
Current
35
Grade D-$2.35-8.5% Hist 90D Ξ±
Trajectory: E (27) β†’ D- (35)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a PEPG Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While PEPG currently carries a cautious 35/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.70) and Max Pain ($2.47) forces dealer call-delta covering toward $8.19.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PEPGβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œPEPG Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 35%NO 65%Trade / Inspect Odds β†’
SEC FORM 4 Γ— 13F HEDGE FUNDS Γ— CONGRESSIONAL STOCK ACT

PEPG Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales β†’
β–² Disclosed Buys: 0 ($0)β–Ό Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (PEPG)

No recent open-market Form 4 cluster sales or emergency dumps flagged on PEPG. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PEPG)

  • βœ“Walkthrough of PEPG's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
PEPG // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +21.76%πŸ›‘οΈ HOLDING TREND SUPPORT
2026-11-04O $2.36H $2.36L $2.35C $2.35VOL 565.9K
RES: $4.34SUP: $2.25SMA50: $2.70SMA200: $2.99
$4.27$3.47$2.67$1.86$1.06RES $4.34SUP $2.25$2.352026-05-052026-06-182026-08-052026-09-212026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PEPG Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ PEPG Butterfly Map β†’ + Track PEPG β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -4.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PEPG today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for PEPG. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PEPG today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PEPG)

Health Care Rank #598 of 1015 βš”οΈ CNTN vs PEPG Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (PEPG vs. CNTN, ANTX, ORMP, YARW)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, PepGen Inc. (PEPG) ranks #598 by composite RQD confidence (35/100, grade D-) and #596 by equity capitalization ($162.8M). Within this direct 5-issuer industry benchmark cohort, PEPG leads on earnings valuation at N/A trailing P/E, while CNTN leads on capital efficiency and profitability with -4.1% ROIC and β€” gross margin. ANTX currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with PEPG at 35/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PEPG ACTIVE
PepGen Inc.
D- 35/100 β€” β€” -35.0% -0.42% $162.8M Benchmark Subject
CNTN
Canton Strategic Holdings Inc.
E 33/100 β€” β€” -4.1% +4.62% $162.5M /cntn-vs-pepg β†’
ANTX
AN2 Therapeutics Inc.
D- 43/100 β€” β€” -35.0% -3.97% $164.2M /antx-vs-pepg β†’
ORMP
Oramed Pharmaceuticals Inc.
E 33/100 β€” 0.7% -7.8% -2.68% $166.4M /ormp-vs-pepg β†’
YARW
Yarrow Bioscience Inc.
E 26/100 β€” β€” -35.0% -9.90% $166.8M /yarw-vs-pepg β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001835597 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), PepGen Inc. (PEPG) reported GAAP revenue of $262.1M (-4.2% vs. FY2024 revenue of $273.7M , and +10.4% cumulative change since FY2023) , GAAP net income of -$89.7M, operating cash flow of -$81.6M, and free cash flow of -$81.9M (+1.2% YoY). On the balance sheet, PEPG closed FY2025 with $173.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $262.1M -$89.7M -$81.6M -$81.9M $173.9M β€”
FY2024 (FY) 2024-12-31 $273.7M -$90.0M -$82.4M -$82.9M $150.9M β€”
FY2023 (FY) 2023-12-31 $237.3M -$78.6M -$69.0M -$69.0M β€” β€”

3. PEPG Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PEPG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, PepGen Inc. (NASDAQ: PEPG) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $2.35 (-0.42% 1D, market cap $162.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, PEPG ranks #598 in composite RQD confidence.

How does PEPG compare to CNTN and ANTX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PEPG carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, CNTN (Canton Strategic Holdings Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -4.1%, cap $162.5M) and ANTX (AN2 Therapeutics Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $164.2M). Among the 5-stock peer group, PEPG leads on earnings multiple (N/A) while CNTN leads on capital efficiency (-4.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PEPG?

Per PEPG's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001835597), PepGen Inc. generated $262.1M in revenue (-4.2% YoY), -$89.7M in net income, and -$81.9M in free cash flow against $173.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PEPG trading relative to its 50-day, 200-day, and 52-week technical levels?

PEPG last traded at $2.35 (-0.42% on volume of 565,921 shares), positioning the stock -12.96% below its 50-day simple moving average ($2.70) and -21.40% below its 200-day simple moving average ($2.99). Across its 52-week range of $1.31 to $7.80, PEPG sits at the 16.0% percentile with a 14-day RSI of 41.6 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.5% ($2.06 to $2.64).

Direct Sub-Reports: PEPG RQD Cockpit PEPG 12M Forecast PEPG Earnings & Move PEPG Dividends & DRIP PEPG Insiders & 13F PEPG Whale Options PEPG Profit Sankey PEPG News & Why
ROARABLE RATING BRIEF β€’ RQD 35/100 (D-) βœ“ SEC XBRL & RQD VERIFIED

PEPG β€” PepGen Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

PepGen Inc. (PEPG) earns a live Roarable RQD composite score of 35/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $2.35 (-0.42% 1D, market capitalization $162.8M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of β€”, operating margin of β€”, and free cash flow yield of β€”.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

PepGen Inc. (PEPG) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Reported revenue is β€” in each of the listed fiscal years, . Market capitalization is recorded as $166.9M in the market data and approximately $0.2B in the profile.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), PepGen Inc. (PEPG) reported $262.1M in annual revenue (up from $273.7M in FY2024, -4.2% YoY) and -$89.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($237.3M revenue, -$78.6M net income) through FY2025, PEPG scaled operating cash flow to -$81.6M and free cash flow to -$81.9M, backed by $173.9M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D- β€’ RQD 35/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of β€” and institutional whale pillar of 3/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.31 – $7.80 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against β€” operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), PEPG carries a macro regime beta of 1.00 and gross margin of β€”.

  • Key Question #1: Can PEPG sustain or expand its β€” operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $262.1M and free cash flow of -$81.9M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is PEPG's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

PEPG Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for PepGen Inc. (PEPG) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to PEPG Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PEPG Bull vs. Bear Conversation Board β€” What's Your Call at $2.35?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PEPG 🐻 33% BEARISH CONVICTION
1. Pick Your Side on PEPG:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER β€’ Options Flow Specialist πŸ‚ BULLISH 🎯 Target: $2.93 (+24.2%)
πŸ“Œ Pinned Debate

PGN-EDODM1 data is flagged in the news wire as a major inflection point, and cash rose to $60.5M in FY 2025.

Here is why I am bullish on PEPG here at $2.36: PGN-EDODM1 data is flagged in the news wire as a major inflection point, and cash rose to $60.5M in FY 2025.. Compare PEPG's 0.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $2.24 are getting bought.

CapAlloc_Nerd πŸ‚ BULL

@FadeTheHype Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

FA FadeTheHype RQD DEBATE OPENER β€’ Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $1.82 (-22.9%)
Spot @ $2.36

ROIC of -35%, FCF of -$81.9M in FY 2025, and an RQD score of 38 indicate ongoing cash burn without revenue.

I respect the product at PepGen Inc., but the stock at $2.36 is a different story. ROIC of -35%, FCF of -$81.9M in FY 2025, and an RQD score of 38 indicate ongoing cash burn without revenue.. FCF yield is 0.0% and RQD sits at 35/100 (D-) β€” why pay up here when you can wait for next quarter's numbers?

LIVE TAPE